

#NephJC Transcript

Healthcare social media transcript of the #NephJC hashtag.

Wed, April 24th 2019, 10:30AM – Wed, April 24th 2019, 1:30PM (America/Toronto).

See #NephJC Influencers/Analytics.



Dr.Fahmi Al-Dhaheri @fa7mi77

4 days ago

RT @aishaikh: The #CREDESCENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Dr Kishan @nephdrkishan

4 days ago

RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>



Mohamed E. Elrggal @M_Elraggal

4 days ago

This is clever #NephJC #CREDESCENCE #CredenceCraze



Fra Ian @caioqualunque

4 days ago

RT @Nephro_Sparks: the next several years will teach us alot about SGLT2i inpatients with CKD. We need to keep our antennae up and ensure w...



Nephrology Jrnl Club @NephJC

4 days ago

SGLT inhibitors in focus at today's #Nephjc. Let us revisit the mechanism of action in brief. Photo courtesy - <https://t.co/cAHJ9tV6iw> <https://t.co/f54zGLh06r>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

Check this awesone thread to see author's @VladoPerkovic responses during US chat today morning. Stay tuned for Asian chat in one hour 9pm Ist #NephJC



Hector Madariaga @HecmagsMD

4 days ago

RT @c8lynv: Visual summary of the epic CREDESCENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>

Nephrology Jrnl Club @NephJC

4 days ago



SGLT2i work in the proximal tubule where they selectively block the SGLT2 inhibitors and reduce the reabsorption of glucose thereby reducing the renal threshold for glucose excretion. Renal threshold is increased in diabetics #nephjc
<https://t.co/7lwOswYVp8>

Nephrology Jrnl Club @NephJC


4 days ago



And Canaglifozin reduces this threshold causing glycosuria (glycoretic) #NephJC
<https://t.co/eTL9JUMd99>

Laura Slattery @Slatts_1

4 days ago



RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>

Nephrology Jrnl Club @NephJC

4 days ago



By causing increased delivery of sodium to the distal tubule, it cause activation of TGF and afferent arteriolar constriction, thereby reducing glomerular pressure and hyperfiltration #NephJC

Hector Madariaga @HecmagsMD

4 days ago



RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...

Raj Mehta, MD @raj_mehta


4 days ago



RT @NephJC: SGLT inhibitors in focus at today's #Nephjc. Let us revisit the mechanism of action in brief. Photo courtesy - <https://t.co/cA...>

プリン中村 @Nephronojisan

4 days ago



こういうのを見ると一度でいいから血液の中に入って腎臓に濾過されたいという気持ちが湧いてくる。よね?

Dr Aoife Fleming @FlemingAoife

4 days ago



@kierandalton99 interesting method to present MOA of diabetes class of medications, may be useful

**Naomi Attar** @naomiattar

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...

**Mana** @manasigh

4 days ago

RT @edgarvlermamd: SGLT2 inhibitors: diuretic perspective #Nephpearls #NephJC 🍌
<https://t.co/PmRtYs9MfO> <https://t.co/q3luhBzU5k>

**Mana** @manasigh

4 days ago

RT @edgarvlermamd: Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials ca. 2018...

**Mana** @manasigh

4 days ago

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre...

**Mana** @manasigh


4 days ago

RT @edgarvlermamd: Ongoing trials of SGLT2 Inhibitors of interest to the Nephrology Community ca. 2019 Table by @drlovvgaur #Nephpearls #N...

**Naomi Attar** @naomiattar

4 days ago

RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>

**HJ Yia** @huajern

4 days ago

and I still feel bathing the nephro with sugar is a bad idea.

**Dr Jean Pierre Laroche** @Echoraljpangio

4 days ago

RT @aishaikh: Given the benefits of #SGLT2 Inhibitors in diabetic CKD & heart failure - will these conditions eventually become the 'prima...

**Mostapha Habib Allah** @NephroMostapha

4 days ago

RT @kidney_boy: With all the excitement over SGLT2i and TG Feedback I call for a trial of acetazolamide for renal protection! #PoorMansCana...

**Nephrology Jrnl Club @NephJC**

4 days ago

SGLT2 inhibitors have increasingly drawn attention over the last decade. See this excellent ADKD blog from 2018 by @anna_burgner for an explanation of their mechanism of action #NephJC <https://t.co/vYAJm86YG7>

**Samira Farouk, MD, MS @ssfarouk**

4 days ago

RT @Nephro_Sparks: the next several years will teach us alot about SGLT2i inpatients with CKD. We need to keep our antennae up and ensure w...

**Nephrology Jrnl Club @NephJC**

4 days ago

About 30 mins to go for next #NephJC Hope some of authors can join us?
@VladoPerkovic @jardine_meg Rajiv Agarwal of @IUKidney @gbakris
@DavidCWheeler2 @adeeralevin Check out the excellent summary by @drlovygaur
<https://t.co/4MdXRrwI01>

**Daniela Braga @DaniDundum**

4 days ago

RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>

**Mana @manasigh**

4 days ago

RT @jon_ellison: Dear Nephrologists, I have no clue what #CREDENCE is about. But if you don't follow it up with a hyper-hydration trial (CL...

**Scherly Leon, MD @SLeonMD**

4 days ago

RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>

**Scherly Leon, MD @SLeonMD**

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...

**Mana @manasigh**

4 days ago

RT @NephJC: SGLT2 inhibitors have increasingly drawn attention over the last decade. See this excellent ADKD blog from 2018 by Anna Burgner...



Christos Argyropoulos @ChristosArgyrop

4 days ago

@KSusztak @poyanmehr @VelezNephHepato @lp7777777 @S_brimble @Tiff_Caza
These are the data I tweeted during yesterday's #NephJC The disease is different compared to the past <https://t.co/Q1I0WjOpFM>



guilhermetafuri @guilhermetafur1

4 days ago

RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>



Mana @manasigh

4 days ago

RT @NephJC: Eligibility: Focus on GFR down to 30 Albuminuria #NephJC This was a Nephrology RCT #NephJC <https://t.co/cyKOF1e9Nc>



Mo Alzubaidi @NephrosisMo

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Mayuri Trivedi @MayuriTrivedi80

4 days ago

RT @arvindcanchi: You need to be on #NephTwitter to listen to the chatter and more often than not you pick up something interesting or thou...



Mayuri Trivedi @MayuriTrivedi80

4 days ago

RT @kidney_boy: With all the excitement over SGLT2i and TG Feedback I call for a trial of acetazolamide for renal protection! #PoorMansCana...



Rakshit Tewari @rakshit1207

4 days ago

#NephJC Very true! Economic decisions on behalf of patient be better left for caregivers. @aakashshingada



Mayuri Trivedi @MayuriTrivedi80

4 days ago


RT @divyaa24: Check this awesome thread to see author's @VladoPerkovic responses during US chat today morning. Stay tuned for Asian chat in...



Nephrology Jrnl Club @NephJC

4 days ago

Lets warmup with this poll - <https://t.co/7xH1NUMCjf> Are you already using SGLT2i. Please vote if you haven't already and if yes, what patient population are you currently using it in? #NephJC



nephroVIP @nephroVIP

4 days ago

Kidney wurde soeben publiziert! <https://t.co/JaUcbUMI2R> Vielen Dank an @Hinnerk45 @GefrKamnitzer @71bluflashes #nephjc #maga



Swapnil Hiremath, MD, MPH @hswapnil

4 days ago

RT @NephJC: About 30 mins to go for next #NephJC Hope some of authors can join us? @VladoPerkovic @jardine_meg Rajiv Agarwal of @IUKidney...



George Clinical @george_clinical

4 days ago

RT @NephJC: Kudos to team at @george_clinical for designing this study (planned pre-EMPAREG!) #NephJC thanks to Janssen for funding



Aditya A Joshi @AdiAJoshi

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Nephrology Jrnl Club @NephJC

4 days ago

Good evening everyone! It's 9:00PM IST which means it is time for the Asian #NephJC. Welcome to tonight's discussion. <https://t.co/B9lxAnGmlk>



Nephrology Jrnl Club @NephJC

4 days ago

At the outset, let me tell you this is the 5th anniversary of #NephJC and what a rocking paper to celebrate it with!!! <https://t.co/4hChCK9NRe>



Nephrology Jrnl Club @NephJC

4 days ago

I am @aakashshingada and I'll be your host tonight as we discuss this paper. I'm a nephrologist working in a private group practice in Mumbai with @Ubkhanna. and #NSMC faculty 2019. #NephJC.

Nephrology Jrnl Club @NephJC

4 days ago



Please introduce yourself (even if you're just lurking and following along) and declare any Conflicts of Interests. Don't forget to use the hashtag #NephJC. And here's the quick guide on "How to #NephJC <https://t.co/vznWdH9FCC>

**Lovy @drlovygaur**

4 days ago

Hi this is Lovy from New Delhi.. no COI.. excited as everyone in nephrology is #NephJC

**Sanjeev Nair @Nair_Sanj**

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...

**Lovy @drlovygaur**

4 days ago

RT @NephJC: I am @aakashshingada and I'll be your host tonight as we discuss this paper. I'm a nephrologist working in a private group prac...

**Nephrology Jrnl Club @NephJC**

4 days ago

@drlovygaur hi lovy. welcome to #nephjc Again. Brilliant summary

**Divya Bajpai 🇮🇳 @divyaa24**

4 days ago

Hi Divya here. Nephrologist from Mumbai. No Coi #nephjc

**Krithika Mohan @krithicism**

4 days ago

Krithika from Hyderabad, No COI, super excited !! #NephJC

**Nephrology Jrnl Club @NephJC**

4 days ago

Tonight we will be discussing the CREDENCE trial by @VladoPerkovic @jardine_meg Rajiv Agarwal of @IUKidney @gbakris @DavidCWheeler2 @adeeralevin et al, published in @NEJM this month & presented at LBCT #ISNWCN #NephJC

**Divya Bajpai 🇮🇳 @divyaa24**

4 days ago

Great summary Lovy #nephjc



Kevin J. Fowler @gratefull080504

4 days ago

@gratefull080504 : COI: Gilead, Bayer, Retrophin, Protalix, Hansa, Otsuka, CareDx. Kidney Tx recipient 8-5-04. #nephJC



Lovy @drlovygaur

4 days ago

RT @NephJC: Tonight we will be discussing the CREDENCE trial by @VladoPerkovic @jardine_meg Rajiv Agarwal of @IUKidney @gbakris @DavidCWh...



Hector Madariaga @HecmagsMD

4 days ago

Héctor Madariaga. No COI. Totally lurking today. #CREDENCE #NephJC <https://t.co/ZYjPBbLI96>



Nephrology Jrnl Club @NephJC

4 days ago

The trial results received a thunderous applause and I was lucky to have witnessed this landmark trial presentation live! #NephJC <https://t.co/rCUOy8I7sm>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

As the introductions are going on I take the opportunity to invite everyone to take this quiz on the topic after this #nephjc



Nephrology Jrnl Club @NephJC

4 days ago

@HecmagsMD Hi hector! Thanks for joining! how are you? #nephjc



Sanjeev Nair @Nair_Sanj

4 days ago

@NephJC Sanjeev Nair, Chennai. 2nd time today on #NephJC #CredenceCraze Col: Increasingly convinced we are onto a game changer. But looking fwd to hear reality checks from Indian centres for the study @MMCNephro @drmanishasahay1 @narayansgpginep @srigola751 @sreebhusan



Mya Htwe Nge @mhtwenge

4 days ago

Hi, Mya from 🇲🇲 #nephjc no COI



Nephrology Jrnl Club @NephJC

4 days ago

RT @divyaa24: As the introductions are going on I take the opportunity to invite everyone to take this quiz on the topic after this #nephjc...



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

Hi Manish, Sanjeev, Mya, Welcome to #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

Check out these brilliant #visualabstract s by @MarioFunesMD created for #Nephjc and @brendonneuen created for @georgeinstitute <https://t.co/bw9sjn8p19>



Nephrology Jrnl Club @NephJC

4 days ago

Didn't have time to sift through the entire paper and supplementary material? Check out the excellent summary by @drlovygaur #NephJC <https://t.co/4MdXRrwI01>



Lovy @drlovygaur

4 days ago

RT @Nair_Sanj: @NephJC Sanjeev Nair, Chennai. 2nd time today on #NephJC #CredenceCraze Col: Increasingly convinced we are onto a game chang...



Krishna K Agrawal @agrawalkris

4 days ago

Hi, This is Krishna from Kathmandu, Nepal. No COI to declare here due to interest in Diabetes and Nephrology #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

@Nair_Sanj @MMCNephro @drmanishasahay1 @narayangpginep @srigola751 @sreebhushan Hi Sanjeev! Welcome to #NephJC



Arvind Canchi 🇮🇳 @arvindcanchi

4 days ago

Arvind Canchi, Nephrologist from a sizzling Bangalore. Will lurk. Drowned in work after the holiday that included an excellent #ISNWCN! #NephJC <https://t.co/nBrvL0dghf>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

Wow love it when we have 2 #visualabstracts for one paper. good to see variation #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

@mhtwenge Hi mya! How are you! Glad to have you here! #NephJC

**Nephrology Jrnl Club @NephJC**

4 days ago

Without further ado...let us move onto T0 and the background #NephJC

**Nephrology Jrnl Club @NephJC**

4 days ago

Check out this amazing tweetorial from @aishaikh summarizing all the Q & A with the lead author @VladoPerkovic from the US #Nephjc chat <https://t.co/3WYnQwHiOC>**Arvind Canchi**  @arvindcanchi

4 days ago

RT @divyaa24: As the introductions are going on I take the opportunity to invite everyone to take this quiz on the topic after this #nephjc...

**Nephrology Jrnl Club @NephJC**

4 days ago

@agrawalkris Hi Krishna! Welcome to #NephJC

**Divya Bajpai**  @divyaa24

4 days ago

Hi Kevin @gratefull080504 we r lucky to have a patient voice in the Asian chat
Welcome to #NephJC**Nephrology Jrnl Club @NephJC**

4 days ago

@arvindcanchi Hello sir! So glad to have you with us! #NephJC

**Nephrology Jrnl Club @NephJC**

4 days ago

T0: To say that diabetes & associated complications are an epidemic wud be an understatement. Given that 30-40% of people with diabetes ultimately develop diabetic kidney disease, renal physicians are likely to be treating these individuals with ever increasing frequency #NephJC

**Sanjeev Nair @Nair_Sanj**

4 days ago

@arvindcanchi Bangalore sizzles?! Pfft..what is it..28? #NephJC

**Krithika Mohan @krithicism**

4 days ago

RT @NephJC: Check out these brilliant #visualabstract s by @MarioFunesMD created for #Nephjc and @brendonneuen created for @georgeinstitute...



Mya Htwe Nge @mhtwenge

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Kevin J. Fowler @gratefull080504

4 days ago

@NephJC Don't forget the people living with kidney disease who have suffered from limited treatment options #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@arvindcanchi Great Picture! what exactly is it? #NephJC



Graham Abra, MD @GrahamAbra

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Krithika Mohan @krithicism

4 days ago

RT @NephJC: Check out this amazing tweetorial from @aishaikh summarizing all the Q & A with the lead author @VladoPerkovic from the US #Nep...



Nephrology Jrnl Club @NephJC

4 days ago

T0: Unsurprisingly, this has resulted in a dearth of clinical trials investigating pharmacotherapies to halt or slow the progression of diabetic kidney disease. This excellent graphic by @drlovygaur summarizes the salient trials #NephJC
<https://t.co/ry4Bx9DXIs>



Matt Graham-Brown @DrMattGB

4 days ago

RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@gratefull080504 @NephJC Finally we have something to give hope to our patients. Feels good #NephJC



Arvind Canchi 🇮🇳 @arvindcanchi

4 days ago

@Nair_Sanj Well, it's climbing.... #nephjc <https://t.co/7eS5w2iKwa>



Mayuri Trivedi @MayuriTrivedi80

4 days ago

@NephJC Mayuri Trivedi...nephrologist from Mumbai..No COI...waiting to hear the good the bad and the ugly of the wonder drug!!#NephJC



Vlado Perkovic @VladoPerkovic

4 days ago

@NephJC @aishaikh Hi all, back for more from Vancouver airport- can join for a little while #NephJC . PI for CREDENCE and consulted to most SGLT2i manufacturers



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@MayuriTrivedi80 @NephJC Hi @MayuriTrivedi80 welcome to #nephjc



Sanjeev Nair @Nair_Sanj

4 days ago

Woohoo 1st author in the house #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

T0c: RAS blockade has remained the cornerstone of treatment to delay the progression of diabetic nephropathy. However, despite maximal RAS blockade, proteinuria does not completely regress and a significant proportion of patients progress to kidney failure. #NephJC



Vineet Behera @BeheraVineet

4 days ago

Hi all I m vineet behera..mumbai..no coi #NephJC



Garima Aggarwal @gag_aggarwal

4 days ago

@MayuriTrivedi80 @NephJC Hi Garima Aggarwal here from New Delhi. No coi. Can't keep calm coz we finally have some good news in Diabetic Nephropathy! Thank you for discussing it tonight. Won't be able to participate, but keeping track of the thread #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

WOW first author in #asian #nephjc chat. awesome tonight is the night where all our wishes come true @VladoPerkovic



Nephrology Jrnl Club @NephJC

4 days ago

Applause!! We have the author in the house! Congratulations on such a landmark trial and thank you so much for joining us #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

While there have been many new hypoglycaemic agents introduced in the last 2 decades, few of them have shown effect in altering disease progression. #NephJC



Kevin J. Fowler @gratefull080504

4 days ago

@divyaa24 You are welcome + thank you for your kind comments #nephJC



Krithika Mohan @krithicism

4 days ago

Thanks for joining us @VladoPerkovic #NephJC



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

Hi this is Anant from New Delhi. No COI.. lets c if SGLT2i are game changers like SR Tendulkar who celebrates his Bday today #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

True it must have been a humongous task to complete this multicenter RCT Kudos #nephjc



Kevin J. Fowler @gratefull080504

4 days ago

Checking in from Boston airport on business #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

Linagliptin was renoprotective in several animal models, this has not been replicated in human studies. CARMELINA did not demonstrate evidence of renoprotection. GLP-1 analogues have shown a modest effect on albuminuria, but no effect on GFR or tangible clinical outcomes #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@DrAnantJoshi82 Its #nephjc Bday too. 5 yrs old



Nephrology Jrnl Club @NephJC

4 days ago

Today moving to data from previous studies on SGLT2i - here's a table that summarizes the findings. Also check out previous #Nephjc coverage on Empareg and Canvas <https://t.co/k69ARWHqQn> <https://t.co/ioiLbQwy6U> <https://t.co/aCAmUqDBsx>



Mayuri Trivedi @MayuriTrivedi80

4 days ago

RT @DoctorGates: Currently at #MidwestHeadquarters are discussing why we need to watch out for euglycemic DKA in SGLTi patients. Conse...



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

@divyaa24 Wow!!! Stalwarts share bdays #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

Hi @BeheraVineet @DrAnantJoshi82 @krithicism .. Thanks for joining #NephJC



Arunkumar @Arunkr_Dr

4 days ago

Hi all!! This is Arunkumar from Delhi. No COI #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

RT @NephJC: T0d moving to data from previous studies on SGLT2i - heres a table that summarizes the findings. Also check out previous #Nephj...



Arvind Canchi 🇮🇳 @arvindcanchi

4 days ago

@divyaa24 The Bangalore International Airport named after Kempe Gowda. #nephjc
<https://t.co/302qwUfea7>



Sanjeev Nair @Nair_Sanj

4 days ago

@VladoPerkovic @NephJC @aishaikh I've been told India contibuted the 2nd largest number of pts to he cohort. Is this true? How difficult was it to coordinate a multi-centre trial in the Indian centres #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

RT @Nair_Sanj: Woohoo 1st author in the house #NephJC <https://t.co/mMUWfbOTL8>



Nephrology Jrnl Club @NephJC

4 days ago

RT @Nair_Sanj: @VladoPerkovic @NephJC @aishaikh I've been told India contibuted the 2nd largest number of pts to he cohort. Is this true? H...



Krithika Mohan @krithicism

4 days ago

RT @NephJC: T0d moving to data from previous studies on SGLT2i - heres a table that summarizes the findings. Also check out previous #Nephj...



Vineet Behera @BeheraVineet

4 days ago

@VladoPerkovic @NephJC @aishaikh Great to have you @VladoPerkovic The first author..#nephjc



DEA 🌟 @sayELAINEtso

4 days ago

RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

@KidneyDrSingla @NephJC Being tubulotoxic. And contributing to IFTA in long term #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

One of the significant concerns has been the signal of higher amputations reported in CANVAS - and then reinforced by observational data from elsewhere. #NephJC <https://t.co/XbSjFVc8aW>



Krithika Mohan @krithicism

4 days ago

RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

Can we expect a sub-group analysis of patients from Asia and India particularly? @VladoPerkovic #nephjc



Nephrology Jrnl Club @NephJC

4 days ago

RT @c8lynv: Visual summary of the epic CREDENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>



Vijay Kher @VijayKher8

4 days ago

@NephJC Vijaykher@vijaykher8 , nephrologist from Delhi NCR , no conflicts, will be lurking mostly #NephJC



Vlado Perkovic @VladoPerkovic

4 days ago

@Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to support the sites in India #NephJC <https://t.co/HWtgkq3SHn>



Nephrology Jrnl Club @NephJC

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to...



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to...



Nephrology Jrnl Club @NephJC

4 days ago

CRENENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) was designed to assess the effects of canagliflozin on primarily the renal outcomes in patients with established nephropathy. #NephJC



Arvind Canchi 🇮🇳 @arvindcanchi

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to...



Mayuri Trivedi @MayuriTrivedi80

4 days ago

@VijayKher8 @NephJC Welcome sir..great to have u around..#nephjc



Harini Sarathy @hurryknee

4 days ago

Yes. We increasingly see more non-proteinuric DKD, typically patients on long-standing ACEI/ARB. (Good PCPs I suppose)! Not all non-proteinuric CKD can be slotted into that 'well of "presumed hypertensive nephrosclerosis"'. Need better biomarkers for DKD.



Krithika Mohan @krithicism

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to...



DrRajivSankaranarayanan PhD FESC MRCP MBBS @DrRajivsankar 4 days ago

RT @NephJC: Didn't have time to sift through the entire paper and supplementary material? Check out the excellent summary by @drlovygaur #N...



Harini Sarathy @hurryknee 4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to...



Nephrology Jrnl Club @NephJC 4 days ago

Of note, CREDENCE was initiated in 2014, before the results of EMPAREG came out. Another important point to note was that previous trials tended to enrol patients with preserved GFR due to a theory that efficacy of these agents decreased with decreasing GFR #NephJC <https://t.co/Utt8QKCIWw>



Kevin J. Fowler @gratefull080504 4 days ago

#NephJC For what it is worth my daughter will be teach in Bangalore this summer teaching autistic students



Vlado Perkovic @VladoPerkovic 4 days ago

@divyaa24 Certainly something we will look at for the future, but need to be careful when only few participants are available #NephJC . But results appear consistent by region and ethnicity <https://t.co/vjuDtVnKCU>



Divya Bajpai 🇮🇳 @divyaa24 4 days ago

Hi Dr. Kher @VijayKher8 Welcome to #NephJC Waiting to hear your experience about this drug and yur views about #credence



Divya Bajpai 🇮🇳 @divyaa24 4 days ago

RT @VladoPerkovic: @divyaa24 Certainly something we will look at for the future, but need to be careful when only few participants are avai...



Mayuri Trivedi @MayuriTrivedi80 4 days ago

@VladoPerkovic @Nair_Sanj @NephJC @aishaikh @george_clinical Did we have greater compliance issues and SAE from our population?#nephjc

**Nephrology Jrnl Club @NephJC**

4 days ago

This poll again - <https://t.co/7xH1NV4daN> how many of you are actively using SGLT2i already and how has your experience been? Cost? Adverse events?

**Krithika Mohan @krithicism**

4 days ago

Interesting that nearly 20 % of the south East Asian population in the study was from India #NephJC

**Sanjeev Nair @Nair_Sanj**

4 days ago

@VladoPerkovic @NephJC @aishaikh @george_clinical Are you concerned about the generalizability of these results to South Asians and Africans given the numbers involved? #NephJC

**DrRajivSankaranarayanan PhD FESC MRCP MBBS @DrRajivsankar**
@Wongplan1

4 days ago

**Krithika Mohan @krithicism**

4 days ago

RT @NephJC: Of note, CREDENCE was initiated in 2014, before the results of EMPAREG came out. Another important point to note was that previ...

**Divya Bajpai 🇮🇳 @divyaa24**

4 days ago

@VladoPerkovic Looks like whites and Asian did better than African Americans? #NephJC

**Vlado Perkovic @VladoPerkovic**

4 days ago

@divyaa24 But great job to my Indian colleagues who worked so hard on this trial. And note that India is included in the 'rest of world' analysis where the benefits appear particularly clear #NephJC

**Nephrology Jrnl Club @NephJC**


4 days ago


Onto T1 and the methods #NephJC


**Sanjeev Nair @Nair_Sanj**


4 days ago


RT @VladoPerkovic: @divyaa24 But great job to my Indian colleagues who worked so hard on this trial. And note that India is included in the...


 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @VladoPerkovic: @divyaa24 But great job to my Indian colleagues who worked so hard on this trial. And note that India is included in the...


 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @VladoPerkovic: @divyaa24 Certainly something we will look at for the future, but need to be careful when only few participants are avai...


 **Nephrology Jrnl Club @NephJC** 4 days ago
T1a: This was a randomised, double-blind, placebo-controlled trial conducted at 690 sites in 34 countries across North America, Latin America, South Africa and Asia Pacific. #NephJC

 **Krishna K Agrawal @agrawalkris** 4 days ago
@krithicism Its a rule sort of that any RCT on diabetes drugs requires a certain percentage of Asia population for approval, Is it so? @VladoPerkovic #Nephjc

 **Vlado Perkovic @VladoPerkovic** 4 days ago
@Nair_Sanj @NephJC @aishaikh @george_clinical I think the results can be generalised with confidence given the lack of indication of any variability in response across all the very many subgroups tested. Ultimately this is a limitation of all RCTs #NephJC

 **Divya Bajpai 🇮🇳 @divyaa24** 4 days ago
RT @VladoPerkovic: @divyaa24 But great job to my Indian colleagues who worked so hard on this trial. And note that India is included in the...

 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh @george_clinical I think the results can be generalised with confidence given the lack of i...

 **Nephrology Jrnl Club @NephJC** 4 days ago
T1b Because the trial was designed to study the impact of Canagliflozin on the progression of CKD, the intent was that at least 60% of the patient population have CKD stage 3 (rather than stage 2), with an eGFR of 30-60 ml/min/1.73m2. #NephJC <https://t.co/e90XWs6Jy4>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh @george_clinical I think the results can be generalised with confidence given the lack of i...



Edgar V. Lerma 🇵🇭 @edgarvlermamd

4 days ago

@Maximal_Change @WUNephrology CSG: Effect of ACE inhibition on Diabetic Nephropathy ca. 1993 from @NEJM #VisualAbstract by @PabloGarciaMD #Nephpearls #NephJC 👉 <https://t.co/N9CD7hySbX> <https://t.co/OrUJ2y0b1X>



Kevin J. Fowler @gratefull080504

4 days ago

@NephJC and screened over 12,000 patients #nephJC



Mayuri Trivedi @MayuriTrivedi80

4 days ago

@NephJC When we say placebo how did we achieve glycemic control in the placebo arm?#NephJC



Vlado Perkovic @VladoPerkovic

4 days ago

@MayuriTrivedi80 @Nair_Sanj @NephJC @aishaikh @george_clinical I remember that the investigators from India did a really great job! No greater issues I as far as I can recall #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

T1c Patients who met the eligibility criteria were enrolled in a 2-week, single-blind placebo-run in period. Patients who failed to take $\geq 80\%$ of the scheduled run-in treatment were deemed ineligible. #NephJC



Mayuri Trivedi @MayuriTrivedi80

4 days ago

RT @edgarvlermamd: @Maximal_Change @WUNephrology CSG: Effect of ACE inhibition on Diabetic Nephropathy ca. 1993 from @NEJM #VisualAbstract...



Nephrology Jrnl Club @NephJC

4 days ago

T1d Eligible patients were randomized (1:1) to receive either Canagliflozin (100mg orally once daily) or matching placebo. Randomisation was stratified according to the category of estimated GFR at the time of screening #NephJC <https://t.co/IWwD32kB1D>

Vlado Perkovic @VladoPerkovic

4 days ago



@agrawalkris @krithicism It depends. Different countries have different rules for approval. US generally requires that population representative of broader US population. Some countries (eg. China, Japan) require a set number of participants from that country involved in trials. Its complex #NephJC

Divya Bajpai  @divyaa24

4 days ago



@NephJC Exclusion of pts with K>5.5, well lots of my clinic pts have this (specially on RAASi) ? #nephjc @VladoPerkovic

Krithika Mohan @krithicism

4 days ago



RT @NephJC: T1d Eligible patients were randomized (1:1) to receive either Canagliflozin (100mg orally once daily) or matching placebo. Rand...

Nephrology Jrnl Club @NephJC

4 days ago



Glycemic control was reinforced with diet, exercise counselling and also as per the discretion of the responsible physician. Patients were followed up at 3, 13 and 26 weeks, then alternated between telephone calls and out-patient visits every 13 weeks. #NephJC

Lovy @drlovygaur

4 days ago



RT @krithicism: Interesting that nearly 20 % of the south East Asian population in the study was from India #NephJC

Divya Bajpai  @divyaa24

4 days ago



@MayuriTrivedi80 @NephJC there was higher use of insulin and other OHAs in placebo arm. at the end HBA1c was not much differnet #nephjc

Nephrology Jrnl Club @NephJC

4 days ago



Lead author suggests Side effect profile similar in Indian patients too. Cost is something that is a challenge but for drug with such unequivocal benefit, strategies may evolve #NephJC

Sanjeev Nair @Nair_Sanj

4 days ago



@NephJC How much debate went into this 80% cut-off for the run-in @VladoPerkovic ? #NephJC Increased rigour for the study but harsh logistically?



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

@divyaa24 @NephJC @VladoPerkovic Diabetics more prone possibly due to type 4 RTA #NephJC



alena md @alenapiasmd

4 days ago

@sayELAINEtso eto yung gamot na hindi ka nga madadialysis, pero putol naman paa mo 🙄🙄🙄🙄



Vlado Perkovic @VladoPerkovic

4 days ago

@divyaa24 @MayuriTrivedi80 @NephJC Correct- we specifically asked investigators to do their best to manage patients to local targets, and they did a great job #NephJC



Mayuri Trivedi @MayuriTrivedi80

4 days ago

@divyaa24 @NephJC @VladoPerkovic Agreed to both #nephjc



Nephrology Jrnl Club @NephJC

4 days ago

T1e Primary and secondary Outcomes were as follows #NephJC
<https://t.co/K4cjxZJ1ps>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@NephJC We see people using equally costly other OHAs. If nephroprotection is a reality then it is justified #nephjc



Vlado Perkovic @VladoPerkovic

4 days ago

@divyaa24 @NephJC When we started the study, the data on effects of SGLT2i on K was mixed. Much clearer now that K levels are reduced if anything #NephJC



Nephrology Jrnl Club @NephJC

4 days ago


Any questions and ideas about the methods?? #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

RT @VladoPerkovic: @divyaa24 @NephJC When we started the study, the data on effects of SGLT2i on K was mixed. Much clearer now that K level...



Laura Slattery @Slatts_1
Fantastic visual summary by @c8lynv

4 days ago



Nephrology Jrnl Club @NephJC
@divyaa24 wholeheartedly agree.. And if we delete drugs from prescription with unequivocal benefits (read ketoanalogues etc) we can easily fit SGLT2i in.. #NephJC

4 days ago



Nephrology Jrnl Club @NephJC
RT @VladoPerkovic: @divyaa24 @NephJC When we started the study, the data on effects of SGLT2i on K was mixed. Much clearer now that K level...

4 days ago



Divya Bajpai 🇮🇳 @divyaa24
@VladoPerkovic @NephJC So they can be safely combined with RAASi even when K > 5.5 ? #nephjc

4 days ago



Mayuri Trivedi @MayuriTrivedi80
Real life scenarios for a wonder drug 'credence'..hopefully strategies for cost reduction come soon

4 days ago



Vineet Behera @BeheraVineet
@divyaa24 @NephJC Agree.. the cost is worth the reno protection #nephjc

4 days ago



Nephrology Jrnl Club @NephJC
T2a: Moving to results In terms of baseline demographics, all patients had diabetic nephropathy with duration of diabetes ~ 15.5 years. About two-thirds were on insulin and over half on metformin. #NephJC <https://t.co/R4x7HNqOJG>

4 days ago



Sanjeev Nair @Nair_Sanj
RT @VladoPerkovic: @divyaa24 @NephJC When we started the study, the data on effects of SGLT2i on K was mixed. Much clearer now that K level...

4 days ago



Arvind Canchi 🇮🇳 @arvindcanchi
RT @VladoPerkovic: @divyaa24 @NephJC When we started the study, the data on effects of SGLT2i on K was mixed. Much clearer now that K level...

4 days ago

Vlado Perkovic @VladoPerkovic

4 days ago



@Nair_Sanj @NephJC This was pretty simple- if a participant couldn't take a placebo tablet for 2 weeks, they were unlikely to take study treatment for years and would therefore reduce study power. Will have to check the numbers but don't think it excluded many #NephJC

Divya Bajpai  @divyaa24

4 days ago



@NephJC Yes and also the CKDMBD brigade. #nephjc

Kevin J. Fowler @gratefull080504

4 days ago



#NephJC Have to run and catch a plane

Nephrology Jrnl Club @NephJC

4 days ago



T2b Despite the 30 ml/min GFR floor, about 170 participants with GFR 15-30 were included. 10% had nephrotic range proteinuria and another three-quarters had non-nephrotic, but macroalbuminuria. #NephJC <https://t.co/63YTgCI9iO>

Krithika Mohan @krithicism

4 days ago



RT @NephJC: T2a: Moving to results In terms of baseline demographics, all patients had diabetic nephropathy with duration of diabetes ~ 15....

Vineet Behera @BeheraVineet

4 days ago



@NephJC Why was dual RAAS blockade taken as an exclusion ? #nephjc
@VladoPerkovic @divyaa24 @MayuriTrivedi80

Vlado Perkovic @VladoPerkovic

4 days ago



@MayuriTrivedi80 @NephJC Treating doctors could use any non-SGLT2i glucose lowering drug they wanted to in both arms, in order to achieve recommended targets #NephJC

Freely Filtered: A NephJC Podcast @NephJC_Podcast

4 days ago



Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today, and tune in this weekend to Freely Filtered, our Podcast where @kidney_boy @hswapnil @ssfarouk @jenniejlin and @Nephro_Sparks will dissect the study further.

**Nephrology Jrnl Club** @NephJC

4 days ago

T2b By the time all events were adjudicated and recorded ~ 500 primary outcome events had occurred. #NephJC

**Mayuri Trivedi** @MayuriTrivedi80

4 days ago

@BeheraVineet @divyaa24 @NephJC Agree to all the benefits...worried about compliance due to cost...#nephjc

**Samira Farouk, MD, MS** @ssfarouk

4 days ago

RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...

**Vlado Perkovic** @VladoPerkovic

4 days ago

@BeheraVineet @NephJC @divyaa24 @MayuriTrivedi80 Concerns from a number of trials that it might increase risks with no clear benefits identified #NephJC

**Dr. Anant Joshi** @DrAnantJoshi82

4 days ago

@divyaa24 @NephJC Cumulative costs of nephropathy, RRT modalities and associated commodities is prohibitive.. Tilts the scale somewhat in favor of the new molecule #NephJC

**Lovy** @drlovygaur

4 days ago

@BeheraVineet @NephJC @VladoPerkovic @divyaa24 @MayuriTrivedi80 Yes.. infact concurrent aldosterone blockade and renin inhibitors were excluded #NephJC

**Divya Bajpai** 🇮🇳 @divyaa24

4 days ago

@gratefull080504 Have a safe flight. See you in future Asian #nephjc chats

**Nephrology Jrnl Club** @NephJC

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC This was pretty simple- if a participant couldnt take a placebo tablet for 2 weeks, they were unlikel...

**Vineet Behera** @BeheraVineet

4 days ago

@NephJC Upto what egfr cutoff was metformin used ? #nephjc @VladoPerkovic #CREDENCE

Nephrology Jrnl Club @NephJC

4 days ago



There was a 30% relative risk reduction in primary comp end-point of ESKD, doubling of creat & renal CV death, with lines diverging as early as 12 mths after randomization (event rate – 43.2 vs 61.2 per 1000 patient-years respectively in canagliflozin vs placebo arms) #NephJC <https://t.co/OFpeOm0Q69>

**Mayuri Trivedi @MayuriTrivedi80**

4 days ago

@divyaa24 @VladoPerkovic @NephJC That is really a relief ..#nephjc

**Sanjeev Nair @Nair_Sanj**

4 days ago

@BeheraVineet @NephJC @VladoPerkovic @divyaa24 @MayuriTrivedi80 Almost all the evidence points to increase MACE with dual RAASi #NephJC

**Nephrology Jrnl Club @NephJC**

4 days ago

@gratefull080504 have a safe flight! thanks for joining! #NephJC

**Vlado Perkovic @VladoPerkovic**

4 days ago

@divyaa24 @NephJC We dont have clear data but I would not be worried about this. By delivering more sodium to distal tubule, they should lead to increased K clearance and this is what the data suggest. But sensible to watch closely #NephJC

**Nathaniel Reisinger @nephrothaniel**

4 days ago

RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...

**Vineet Behera @BeheraVineet**

4 days ago

RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...

**Nephrology Jrnl Club @NephJC**

4 days ago

T2d The relative risks of ESKD, doubling of serum creatinine and death due to cardiovascular cause were reduced by 32%, 40% and 22% respectively. #NephJC <https://t.co/xBwKDKCcJ9>



Arvind Canchi 🇮🇳 @arvindcanchi

4 days ago

RT @VladoPerkovic: @divyaa24 @NephJC We dont have clear data but I would not be worried about this. By delivering more sodium to distal tub...



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

Seeing the results do you think the use can be extended to lower GFR like upto 20ml/min? @VladoPerkovic #nephjc



Mayuri Trivedi @MayuriTrivedi80

4 days ago

@BeheraVineet @NephJC @VladoPerkovic @divyaa24 Osmotic diuresis May lead to greater hypotensive episodes with dual block...😞😞😞..just guessing #nephjc



Nephrology Jrnl Club @NephJC

4 days ago

@VladoPerkovic @MayuriTrivedi80 This is the list of OHAs used #NephJC
<https://t.co/qxNPUt98hb>



Nephrology Jrnl Club @NephJC

4 days ago

T2e With respect to relative risk reduction in the primary outcomes, the effect was consistent across all subgroups on subgroup analysis #NephJC
<https://t.co/qZMy2D21Ft>



Vlado Perkovic @VladoPerkovic

4 days ago

@BeheraVineet @NephJC We relied on local guidelines- varied from 30-60 mls/min, and also changed a bit in some countries during the course of the trial #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago


@BeheraVineet @NephJC @VladoPerkovic @MayuriTrivedi80 Why would you like to give dual RAASi to DKD ? #nephjc





Nephrology Jrnl Club @NephJC


4 days ago


RT @VladoPerkovic: @divyaa24 @NephJC We dont have clear data but I would not be worried about this. By delivering more sodium to distal tub...


 **Sanjeev Nair** @Nair_Sanj 4 days ago
@VladoPerkovic @divyaa24 @NephJC Could we go so far as saying in a DN pt on ACEi/ARBs with HyperK it might be therapeutically smart to add a SGLT2i to also help with the K? #NephJC #Reaching


 **Krithika Mohan** @krithicism 4 days ago
RT @NephJC: @VladoPerkovic @MayuriTrivedi80 This is the list of OHAs used #NephJC <https://t.co/qxNPUt98hb>


 **Alison Gifford** @alisonmgifford 4 days ago
RT @PedCritCareMed: *FREE* Feature: In #pediatric #ARDS, elevations in day 3 cumulative fluid balance are associated with #mortality among...



 **Nephrology Jrnl Club** @NephJC 4 days ago
RT @DrAnantJoshi82: @divyaa24 @NephJC Cumulative costs of nephropathy, RRT modalities and associated commodities is prohibitive.. Tilts the...


 **Vlado Perkovic** @VladoPerkovic 4 days ago
@divyaa24 I think the results for the 30-45mls/min eGFR subgroup mean that the drug is promising for lower eGFR levels. But risks could be higher so wouldnt start below 30 until more data. Note that patients who had eGFR drop below 30 during #CREDESCENCE continued study treatment #NephJC


 **Nephrology Jrnl Club** @NephJC 4 days ago
T2f: The degree of albuminuria was 31% lower compared with placebo. This difference appears almost immediately, suggesting an early hemodynamic mechanism probably mediated by reduced intraglomerular pressure. #NephJC <https://t.co/ANgA3rZpn0>


 **Sanjeev Nair** @Nair_Sanj 4 days ago
@NephJC Such beautiful pictures... sigh.. #NephJC



 **Vlado Perkovic** @VladoPerkovic 4 days ago
@Nair_Sanj @divyaa24 @NephJC Stretching a bit indeed- I dont think any K effect is strong enough to be therapeutically useful #NephJC


 **Divya Bajpai**  @divyaa24 4 days ago
@Nair_Sanj @VladoPerkovic @NephJC there is some data with Hyperkalemia with #SGLT2i. Need to evaluate this, but physiologically makes sense that it should decrease K+ #nephjc


 **Jhonatan Velador Mendoza** @jhonatanmd82 4 days ago
RT @NefroHUVmaca: Excelente revisión de los estudios realizados en enfermedad renal diabética en una sola diapositiva ! #CKD #diabetes @Cr...


 **Judith López** @Judithendo 4 days ago
RT @NefroHUVmaca: Excelente revisión de los estudios realizados en enfermedad renal diabética en una sola diapositiva ! #CKD #diabetes @Cr...


 **Toñi Carretón Ballester** @CarretonToni 4 days ago
RT @NephJC: SGLT2 inhibitors have increasingly drawn attention over the last decade. See this excellent ADKD blog from 2018 by Anna Burgner...


 **Divya Bajpai**  @divyaa24 4 days ago
RT @VladoPerkovic: @divyaa24 I think the results for the 30-45mls/min eGFR subgroup mean that the drug is promising for lower eGFR levels....


 **Krithika Mohan** @krithicism 4 days ago
RT @NephJC: T2f: The degree of albuminuria was 31% lower compared with placebo. This difference appears almost immediately, suggesting an e...


 **Vineet Behera** @BeheraVineet 4 days ago
@divyaa24 @NephJC @VladoPerkovic @MayuriTrivedi80 Was this t reason why it was excluded..tht ther is no real benefit #nephjc


 **Nephrology Jrnl Club** @NephJC 4 days ago
T2g: While the mean HBA1C levels were lower in Canagliflozin arm the difference was marginal. The mean difference in systolic & diastolic BP were 3.30/0.95 mmHg, lower in the Cana arm. Again, this is too small a difference to result in such a large nephroprotective effect #NephJC <https://t.co/tv1RYpYQJp>


 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...


 **Krithika Mohan @krithicism** 4 days ago
RT @NephJC: T2g: While the mean HBA1C levels were lower in Canagliflozin arm the difference was marginal. The mean difference in systolic &...


 **Vlado Perkovic @VladoPerkovic** 4 days ago
@KidneyDrSingla @NephJC #nephjc <https://t.co/1tgIHBj378>


 **Nephrology Jrnl Club @NephJC** 4 days ago
T2h: In terms of adverse events, amputations & fracture rates were similar across both groups. #NephJC <https://t.co/BFCDzuiLql>

 **Sanjeev Nair @Nair_Sanj** 4 days ago
RT @VladoPerkovic: @divyaa24 I think the results for the 30-45mls/min eGFR subgroup mean that the drug is promising for lower eGFR levels....

 **Divya Bajpai 🇮🇳 @divyaa24** 4 days ago
neither nephro nor CV protection is due to BP or HBA1c lowering #nephjc

 **Nephrology Jrnl Club @NephJC** 4 days ago
@BeheraVineet @divyaa24 @VladoPerkovic @MayuriTrivedi80 There was a signal of harm in so many previous studies. And it is not standard of care in any case. why would you want to give dual ras blockade in the first place? #NephJC

 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @divyaa24: neither nephro nor CV protection is due to BP or HBA1c lowering #nephjc <https://t.co/YNncUfNc3K>

 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @VladoPerkovic: @KidneyDrSingla @NephJC #nephjc <https://t.co/1tgIHBj378>

Nephrology Jrnl Club @NephJC

4 days ago



T2i: Ketoacidosis was detected with greater frequency in the Cana arm. Overall the UTIs occurred at similar frequencies in both arms (48 vs 45 episodes per 1000 patient-years). However, genital mycotic infections occurred more commonly in patients receiving Cana. #NephJC <https://t.co/sa7d4sx8X1>

Mayuri Trivedi @MayuriTrivedi80

4 days ago



@NephJC I want to get these figures tattooed on my forehead...sheer beauty #nephjc

OmarTaco MD, MSc @Errantnephron

4 days ago



RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...

Divya Bajpai 🇮🇳 @divyaa24

4 days ago



So is renal death is due to uremia? Too sick to initiate HD or its not available? Interesting #nephjc

Ajaya @Renaltubules

4 days ago



Endo or Nephro who decides to prescribe Canagliflozin 🙄 #NephJC

Sanjeev Nair @Nair_Sanj

4 days ago



@NephJC So the renoprotective effect is independent of glycemic control #NephJC #TheSecretWasAlwaysWithinTheKidney

NephrologyTweets @NephrologyTweet

4 days ago



RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉 <https://t.co/tP3NduZZ...>

Jennie Lin, MD MTR @jenniejlin

4 days ago



RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...

Lovy @drlovygaur

4 days ago



I was wondering if there's any specific reason as to why the benefit seemed to be greater with eGFR 45-60 than other subgroups? And also for the subgroup with albuminuria > 1g/day @VladoPerkovic #nephjc



Dr Manish Singla @KidneyDrSingla

4 days ago

@NephJC Is incidence of UTI different among different gliflozins #NephJC



Nephrology Jrnl Club @NephJC

4 days ago

T2j: Share your thoughts on the results and lets move to discussion? #NephJC



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@Renaltubules In our institute both do. We are acutally planning a combined JC for both the departments #nephjc



Vlado Perkovic @VladoPerkovic

4 days ago

Gotta run for my next flight- thanks for your interest in #CREDESCENCE and hope the rest of the chat goes well #NephJC



Notorious G.A.B. 🐝 @CBgalGab

4 days ago

RT @c8lynv: Visual summary of the epic CREDESCENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>



Mayuri Trivedi @MayuriTrivedi80

4 days ago

Hmmmm..this is a little disturbing and what do we do to overcome it??#nephjc



Nephrology Jrnl Club @NephJC

4 days ago

@Nair_Sanj and independent of BP control.. Difference too little #NephJC



Krithika Mohan @krithicism

4 days ago

why was there a higher incidence of breast cancer in the Cana group? #NephJC



Tom @Tom_MD_

4 days ago

RT @NephJC: T2f: The degree of albuminuria was 31% lower compared with placebo. This difference appears almost immediately, suggesting an e...



Vineet Behera @BeheraVineet

4 days ago

@NephJC About diabetic ketoacidosis.. It will be interesting to know.. Was it higher in the subgroup on insulin or on metformin with sglT2i.. #nephjc @VladoPerkovic

**Divya Bajpai**  @divyaa24

4 days ago

@VladoPerkovic Thanks for joining and congratulations for your great work #nephjc

**Dr Manish Singla** @KidneyDrSingla

4 days ago

Is mycotic genital infection rate different among gliflozins

**Sanjeev Nair** @Nair_Sanj

4 days ago

@NephJC The change in protocol to screen pts for foot ulcers was made mid-trial right? #NephJC @VladoPerkovic

**Adam Segal** @amsegalmd

4 days ago

This thread is tremendously helpful!

**Divya Bajpai**  @divyaa24

4 days ago

@Nair_Sanj @NephJC @VladoPerkovic true #nephjc

**Nephrology Jrnl Club** @NephJC

4 days ago

T3a: The authors conclude that patients with T2DM and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years #NephJC

**Diana Mina** @DiMiRenalMD

4 days ago

RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...

**Nephrology Jrnl Club** @NephJC

4 days ago

@VladoPerkovic Thank you so much for joining and answering the questions!!! Congratulations again! #NephJC

**Dr Manish Singla** @KidneyDrSingla

4 days ago

@VladoPerkovic Thanks #NephJC

**Lovy @drlovygaur**

4 days ago

@NephJC When we say genital mycotic infections- would agree that it is easily treatable, but should we be concerned about recurrence, more so because glucosuria would always be a constant factor? #NephJC

**Vineet Behera @BeheraVineet**

4 days ago

@divyaa24 @Renaltubules Our centre too.. Both give sglT2i Endo nephro nd even cardio #nephjc

**Krithika Mohan @krithicism**

4 days ago

@BeheraVineet @NephJC @VladoPerkovic was wondering the same #NephJC

**Nephrology Jrnl Club @NephJC**

4 days ago

T3b: Is it time to get excited about these medications? Will they be part of our prescribing armamentarium? #NephJC

**Divya Bajpai 🇮🇳 @divyaa24**

4 days ago

@drlovygaur @NephJC our pts will not report this also easily #nephjc

**Nephrology Jrnl Club @NephJC**

4 days ago

@krithicism Not significant #NephJC

**Vineet Behera @BeheraVineet**

4 days ago

@VladoPerkovic Thanks for joining.. Thank you to the entire #CREDENCE team for the landmark trial #nephjc

**Nephrology Jrnl Club @NephJC**

4 days ago

T3c Strengths of the study include 1. The primacy given to renal outcomes 2. Benefit over and above RAS blockade was examined 3. Large clinical trial population #NephJC

**Sanjeev Nair @Nair_Sanj**

4 days ago

@Renaltubules Its a renal drug..Do not cede ground! #NephJC

Nephrology Jrnl Club @NephJC

4 days ago



T3d: Limitations include 1. Premature termination of the trial limited the power for at least some secondary outcomes 2. As with most trials, those with advanced kidney disease (GFR < 30) were excluded from the study, though a few patients with GFR 15-30 did make it in. #NephJC

Shalabh Srivastava @Shalabh_Sriv

4 days ago



RT @aishaikh: The #CRENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...

Krithika Mohan @krithicism

4 days ago



@NephJC I sure as hell hope so ! #NephJC

Nephrology Jrnl Club @NephJC

4 days ago



T3e: This raises a question of generalisability and to consider at what GFR (if any) would one not use or stop an SGLT2i. #NephJC

Divya Bajpai 🇮🇳 @divyaa24

4 days ago



@NephJC Future trials coming up like SCORED to evaluate #SGLT2i in GFR <30ml/min #nephjc

Sanjeev Nair @Nair_Sanj

4 days ago



@NephJC Duh! #NephJC

Vineet Behera @BeheraVineet

4 days ago



@NephJC Truly promising indeed.. my sgl2i prescription has already gone up #nephjc

Sanjeev Nair @Nair_Sanj

4 days ago



@divyaa24 @drlovygaur @NephJC Explain the possibility at the start of treatment. In any case given the cost I suspect there will be protracted discussions regarding this drug from the get go #NephJC

Nephrology Jrnl Club @NephJC

4 days ago



RT @divyaa24: @NephJC Future trials coming up like SCORED to evaluate #SGLT2i in GFR <30ml/min #nephjc

Nephrology Jrnl Club @NephJC

4 days ago



Are you reassured by the safety data, particularly that relating to amputations? How do you envisage these results will change your clinical practice? #NephJC

Nephrology Jrnl Club @NephJC

4 days ago



RT @Nair_Sanj: @divyaa24 @drlovygaur @NephJC Explain the possibility at the start of treatment. In any case given the cost I suspect there...

Divya Bajpai 🇮🇳 @divyaa24

4 days ago



Im still worried about sideeffects. hence it requires close screening and counselling of pts to pick up S/E fast. Also not many of my pts can afford it at present #nephjc

Krithika Mohan @krithicism

4 days ago



@NephJC I would maybe not use in GFR <30 #NephJC

Dr. Anant Joshi @DrAnantJoshi82

4 days ago



@Nair_Sanj @Renaltubules Smashed into the stands with clear ease 🙌🙌🙌
#NephJC

Sanjeev Nair @Nair_Sanj

4 days ago



@NephJC But those with lower GFRs and more proteinurias seemed to do better. So this is a (for now) limitation. Till we get more data #NephJC

Yvelynne Kelly @YvelynneKelly

4 days ago



RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>

Nephrology Jrnl Club @NephJC

4 days ago



Heres a list of future SGLT2i trials #NephJC <https://t.co/Ey1gAvBIZY>

Divya Bajpai 🇮🇳 @divyaa24

4 days ago



RT @NephJC: Heres a list of future SGLT2i trials #NephJC <https://t.co/Ey1gAvBIZY>

Nephrology Jrnl Club @NephJC

4 days ago



Final few minutes: what are your take-home points? #NephJC



Raul Reyna @raul_reyna

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Vineet Behera @BeheraVineet

4 days ago

@NephJC I think.. sglT2i and RASi.. each may have independent benefit.. #nephjc #CREDENCE @VladoPerkovic <https://t.co/BgyVygfZ6o>



Sanjeev Nair @Nair_Sanj

4 days ago

@NephJC I suspect usage will be a bit like Metformin..watch closely even after it drops <30 and stop if adverse effects #NephJC



Krishna K Agrawal @agrawalkris

4 days ago

Any fournier gangrene #NephJC



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

@divyaa24 Wish the increase in infection burden don't spur an increase in drug resistance and mixing of microbes causing community and hospital acquired infection #NephJC



Fra Ian @caioqualunque

4 days ago

RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...



Nephrology Jrnl Club @NephJC

4 days ago

@BeheraVineet @VladoPerkovic oh they do.. The placebo arm showed gfr decline similar to that seen in the RENAAL study. So Cana proved to be better after Diabetes treatment was OPTIMISED in both grps #nephjc



Arvind Canchi 🇮🇳 @arvindcanchi

4 days ago

RT @Nair_Sanj: While u are waiting for today's milestone #NephJC to start, check out this quiz on SGLT2is by @ISNeducation. Didnt do too ba...



Vineet Behera @BeheraVineet

4 days ago

@Nair_Sanj @NephJC Yes.. beneficial effect of sglT2i is n 2 ways.. #nephjc #CREDENCE @VladoPerkovic <https://t.co/fPWtWE1B7u>

Nephrology Jrnl Club @NephJC

4 days ago



I would like to again thank @drlovygaur for the summary and @ MarioFunesMD for the VA. #NephJC

Nephrology Jrnl Club @NephJC

4 days ago



@Nair_Sanj @VladoPerkovic yep A protocol amendment asked investigators to examine patients' feet at each trial visit and temporarily interrupt the assigned treatment in patients with any active condition that might lead to amputation. #NephJC

Dr Manish Singla @KidneyDrSingla

4 days ago



@NephJC how about its use in post renal transplant patients. I am using in some patients #NephJC

Krithika Mohan @krithicism

4 days ago



@NephJC None of them include GFR<15 #NephJC

Dr. Anant Joshi @DrAnantJoshi82

4 days ago



@NephJC @drlovygaur Both were excellent.. What a drug bringing new hope on the horizon deserve #NephJC

Divya Bajpai 🇮🇳 @divyaa24

4 days ago



Take Home: Drug definitely is promising better results with lower GFR >30ml/min and Prot >1g/day but will do extensive screening of pts for prior DKA, Infections, PVD. explain them the S.E, will ask them to look out proactively for S?E, and wish for the cost to come down #nephjc

Vineet Behera @BeheraVineet

4 days ago



@krithicism @NephJC Yes.. me too wil use upto gfr >30 #nephjc

Nephrology Jrnl Club @NephJC

4 days ago




Please also sign up for our weekly newsletter at <https://t.co/5aumn8ImwF> #NephJC


Divya Bajpai 🇮🇳 @divyaa24


4 days ago





RT @Nair_Sanj: While u are waiting for today's milestone #NephJC to start, check out this quiz on SGLT2is by @ISNeducation. Didnt do too ba...


 **Nephrology Jrnl Club @NephJC** 4 days ago
@KidneyDrSingla please share your experience.. Any increased risk of infections in ur patients? #NephJC


 **Lovy @drlovygaur** 4 days ago
RT @BeheraVineet: @Nair_Sanj @NephJC Yes.. beneficial effect of sglt2i is n 2 ways.. #nephjc #CREDESCENCE @VladoPerkovic <https://t.co/fPWtWE1B...>


 **Malvinder Parmar @wittykidney** 4 days ago
@NephJC Was their any difference in outcomes - stage 3a vs stage 3b #NephJC likely not assessed


 **Sanjeev Nair @Nair_Sanj** 4 days ago
@NephJC #NephJC But in all seriousness agree with @divyaa24. Prescribe with care and after explaining everything to our pts regarding potential side effects and the need for follow ups <https://t.co/b9nzpAzILC>

 **Nephrology Jrnl Club @NephJC** 4 days ago
Also, #NephJC peeps - did you know we have a podcast? Check out the latest episode here <https://t.co/Zva3nfrDrK> <https://t.co/vO9W8xRv8P>

 **Nephrology Jrnl Club @NephJC** 4 days ago
RT @divyaa24: Take Home: Drug definitely is promising better results with lower GFR >30ml/min and Prot >1g/day but will do extensive screen...

 **Vineet Behera @BeheraVineet** 4 days ago
@KidneyDrSingla @NephJC Oh.. thats interesting.. how is the response ? And any infections ?? #nephjc

 **Nephrology Jrnl Club @NephJC** 4 days ago
Please note - We will have an #AskASN with @jenniejlin next tuesday <https://t.co/RzpTLAA4MC...> #NephJC

 **Nephrology Jrnl Club @NephJC** 4 days ago
Looking for some #NephJC swag? Order it here <https://t.co/eTUrZYjJeY>



renus gratian @renussande

4 days ago

RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>



Nephrology Jrnl Club @NephJC

4 days ago

This is @aakashshingada signing off. Join @Slatts_1 for EU chat in a few hours. Thank you for joining us and good night! #NephJC



Dr Manish Singla @KidneyDrSingla

4 days ago

@NephJC Used in stable graft function patients, one year plus post transplant. Achieved 5kg plus weight loss. No increase in infection. I ask them to take the tablet with two glasses of water. #NephJC



Sanjeev Nair @Nair_Sanj

4 days ago

@NephJC @KidneyDrSingla I think @VladoPerkovic mentioned in the morning discussion that there isn't any data and will need further studies #NephJC



Vineet Behera @BeheraVineet

4 days ago

Thats precisely..the take home message by @divyaa24 of sglT2i #nephjc



Krithika Mohan @krithicism

4 days ago

@KidneyDrSingla @NephJC what about interactions of Cana with tacrolimus ? #NephJC



Krithika Mohan @krithicism

4 days ago

@KidneyDrSingla @NephJC Increase tac levels, how often do you monitor drug levels ? #NephJC



Dr Manish Singla @KidneyDrSingla

4 days ago

@krithicism @NephJC It can increase tac level, but don't know if it's significant, anyway tac level is being monitored. #NephJC



JPS 🍷 @jimjimpau

4 days ago

RT @NephJC: 5 minutes left See major trials coming out in next few years #NephJC <https://t.co/Qk7CCfXDDv>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

@KidneyDrSingla @NephJC paper from global hospital mumbai @BharatVShah1 about use of #sglt2i in transplant <https://t.co/ONGzSa3jbO> #NephJC



Vineet Behera @BeheraVineet

4 days ago

@NephJC @aakashshingada @Slatts_1 Thanks @aakashshingada for the discussion of this hopefully landmark trial.. #nephjc



Vineet Behera @BeheraVineet

4 days ago

RT @divyaa24: @KidneyDrSingla @NephJC paper from global hospital mumbai @BharatVShah1 about use of #sglt2i in transplant <https://t.co/ONGz...>



Dr Manish Singla @KidneyDrSingla

4 days ago

@BeheraVineet #NephJC



Anna Strasma @AStrasma

4 days ago

RT @c8lynv: Visual summary of the epic CREDESCENCE #NephJC hosted last night by @hswapnil. <https://t.co/txC3JJto5S>



Divya Bajpai 🇮🇳 @divyaa24

4 days ago

Thanks @aakashshingada for hosting this interesting chat #nephjc



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

@Nair_Sanj @NephJC @divyaa24 So that's the take home essence, More watchfulness and care in prescription hence, For the 'better' drug gifted by CREDESCENCE. #NephJC



Lovy @drlovygaur

4 days ago

@krithicism @KidneyDrSingla @NephJC Canagliflozin depends very little on CYP systems; principally metabolised by glucuronidation. By this logic interaction with Tac shouldn't be a concern #NephJC



Vineet Behera @BeheraVineet

4 days ago

RT @drlovygaur: @krithicism @KidneyDrSingla @NephJC Canagliflozin depends very little on CYP systems; principally metabolised by glucuronid...

**Lovy @drlovygaur**

4 days ago

RT @divyaa24: @KidneyDrSingla @NephJC paper from global hospital mumbai @BharatVShah1 about use of #sglt2i in transplant <https://t.co/ONGz...>

**Dr Manish Singla @KidneyDrSingla**

4 days ago

@krithicism @NephJC After first year, tac level every 2-3 months. Not sure how significant is this drug interaction. But worth noticing. Will keep a watch. #NephJC

**Krithika Mohan @krithicism**

4 days ago

Thank @aakashshingada for hosting tonights chat ! #NephJC

**JPS @jimjimpau**

4 days ago

RT @edgarvlermamd: @Maximal_Change @WUNephrology CSG: Effect of ACE inhibition on Diabetic Nephropathy ca. 1993 from @NEJM #VisualAbstract...

**Lovy @drlovygaur**

4 days ago

@aakashshingada as usual u did a commendable job hosting this #nephjc wonderful as always!!!

**Sanjeev Nair @Nair_Sanj**

4 days ago

@NephJC @VladoPerkovic So then u have a sub cohort to analyze for amputations before the added rigour was in place? #NephJC Will address some of the concerns voiced earlier today about generalizability to Indian conditions

**Mayuri Trivedi @MayuriTrivedi80**

4 days ago

RT @divyaa24: @KidneyDrSingla @NephJC paper from global hospital mumbai @BharatVShah1 about use of #sglt2i in transplant <https://t.co/ONGz...>

**Mayuri Trivedi @MayuriTrivedi80**

4 days ago

@krithicism @KidneyDrSingla @NephJC Does it interact with tac???anyways the levels of tac are tightly monitored..#nephjc

**Dr Manish Singla @KidneyDrSingla**

4 days ago

Sglt2i in transplant @Vijaykher14 @raja_1980 @DrSachinMittal1 @nanu_singh #NephJC very interesting. <https://t.co/0bHiye0OyP>



Malvinder Parmar @wittykidney

4 days ago

@aishaikh @VladoPerkovic @NephJC @hswapnil @kidney_boy Great work @aishaikh liked how you compiled all the questions during the #NephJc with their responses.



Dr. Anant Joshi @DrAnantJoshi82

4 days ago

Thanks @aakashshingada for a wonderful hosting of the Nephew JC #NephJC



Fadel Alrowaie @fadelrowaie

4 days ago

RT @edgarvlermamd: @Maximal_Change @WUNephrology CSG: Effect of ACE inhibition on Diabetic Nephropathy ca. 1993 from @NEJM #VisualAbstract...



Dean Wallace @DrDeano

4 days ago

#nephjc Dean Wallace, Paediatric Nephrology, UK. I'll be mostly lurking and peeping tonight slight distraction of the Manchester derby game.



moath Abdulaziz @Moath435106553

4 days ago

RT @edgarvlermamd: @Maximal_Change @WUNephrology CSG: Effect of ACE inhibition on Diabetic Nephropathy ca. 1993 from @NEJM #VisualAbstract...



Dom B @dommibertrand

4 days ago

RT @edgarvlermamd: CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre...



Nabin @drNabinBasnet

4 days ago

@Nair_Sanj @Renaltubules If the drug prevents Nephropathy then these patients might never reach Nephrologist #NephJC



Chowkidar Rachit Garg 🇮🇳 @rachitg

4 days ago

RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...



Anna Strasma @AStrasma

4 days ago

RT @aishaikh: 🌟 How do SGLT2 Inhibitors work? 🌟 How does an anti-diabetic drug improve Renal & Cardiovascular outcomes? 🌟 To understand this l...

**Alex Meraz** 🇲🇪 @NephroGuy

4 days ago

RT @drlovygaur: @krithicism @KidneyDrSingla @NephJC Canagliflozin depends very little on CYP systems; principally metabolised by glucuronid...

**Natasha N. Dave** @NatashaNDave

4 days ago

RT @Nephro_Sparks: The #CREDESCENCE numbers: 1,215 Tweets. 334 Participants. 3,641,848 Impressions. April 23rd 2019. More #NephJC 📊 here https...

**Andrés Rincón B** @andresrinconb26

4 days ago

RT @edgarvlermamd: Pre-CREDESCENCE Diabetic Kidney Disease trials and CKD ca. 2015 from @NDTsocial #Nephpearls #NephJC 👉 https://t.co/GxHnBr...

**madree** @madrees007

4 days ago

RT @landmark_neph: Excited for #NephJC and the discussion of the truly Landmark #CREDESCENCE trial! https://t.co/B7Tru2jxKT

**Vaibhav Keskar** @vskeskar

4 days ago

RT @aishaikh: The #CREDESCENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...

**Lovy** @drlovygaur

4 days ago

RT @VladoPerkovic: @Nair_Sanj @NephJC @aishaikh India did very well but so did many other countries. Fortunate to have @george_clinical to...

**Yatharth Properties**™ @YatharthProper1

4 days ago

Real Estate is now the second most important industry in India only after Agriculture in terms of its contribution to the country's GDP. #ModernFarmingTipsByStMSG #RCBvKXIP #property #chandigarh #WednesdayMotivation #DenimDay #wednesdaythoughts #WednesdayWisdom #NephJC #Delas https://t.co/zva3es14zO

**Aisha Shaikh** @aishaikh

4 days ago

RT @NephJC: Check out this amazing tweetorial from @aishaikh summarizing all the Q & A with the lead author @VladoPerkovic from the US #Nep...



madree @madrees007

4 days ago

RT @aishaikh: When will FDA lower the eGFR limit to 30 ml's/min for the use of SGLT2 inhibitors? #NephJC @US_FDA



Swapnil Hiremath, MD, MPH @hswapnil

4 days ago

RT @NephJC_Podcast: Still can't get over all the excitement over CREDENCE? Well ... neither can we! Join the European #NephJC chat today,...



Amit Langote @LangoteAmit

4 days ago

@Renaltubules Anybody who looks at a diabetic with high risk of DMN and CVD should use it. Does it matter if it's a Cardiologist or Nephrologist or Endocrinologist? #NephJC



Mohamed E. Elrggal @M_Elraggal

4 days ago

I slept and couldn't attend the American #NephJC chat, I was driving back home during the Indian one, I won't miss the European. #CREDENCE #CREDENCEcraze



Mohamed E. Elrggal @M_Elraggal

4 days ago

Try to join @elliottkannor @Ahmed_hatab @NephroTube #NephJC



Vaibhav Keskar @vskeskar

4 days ago

RT @aishaikh: 🌟How do SGLT2 Inhibitors work? 🌟How does an anti-diabetic drug improve Renal & Cardiovascular outcomes? 🌟To understand this I...



Pablo Díez @pablo10arias

4 days ago

RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>



Vijay Kher @VijayKher8

4 days ago

@VladoPerkovic Hi Vlado, nice to have u for #nephjc . Have a safe fight.



manuel macia heras @mmacia25

4 days ago

RT @NephJC: check out the awesome schematic from @drlovygaur about the trials and tribulations in DM nephropathy #NephJC <https://t.co/1PApk...>

Samuel Chakola @samuelchakola

4 days ago

RT @GenNextMD: @kdjhaveri @VelezNephHepato @ssfouk @ASNKidney I had patients with stage 4 ckd call this pst week to be put on sglT2i...#N...

Dr. Guillén  @drguillenvargas

4 days ago



RT @edgarvlermamd: CREDESCENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to curre...

Dr. Roberto Collazo @collazor1

4 days ago



RT @landmark_neph: Excited for #NephJC and the discussion of the truly Landmark #CREDESCENCE trial! <https://t.co/B7Tru2jxKT>

Vijay Kher @VijayKher8

4 days ago



@divyaa24 #NephJC , Exciting credence results. 30% reduction in renal endpoints is very promising. As we gain more experience with them they promise to be gamechangers.

Richard Hull @richardphull

4 days ago



RT @aishaikh: The #CREDESCENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper @VladoPerkovic j...


Trinity Kidneys @THKC1

4 days ago



RT @Slatts_1: @NephJC @hswapnil @aakashshingada Looking forward to co-hosting with @Ted_FitzG tonight 👍 #NephJC #CREDESCENCE

Showing 1 to 396 of 396 entries

 #NephJC content from Twitter.

Free Custom Analytics and Transcripts for #NephJC

100,000 Tweets

Symplur has over 100,000 #NephJC tweets going back to April 2014.

Get unrestricted access to all conversations with **Symplur Signals**.

©2019 Symplur LLC – Connecting the dots in healthcare social media